Leerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).The analyst comments "Bottom ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Vaxcyte, Inc. (PCVX) Tops Q3 EPS by 27cNovember 5, 2024 4:50 PM Form 144 Vaxcyte, Inc. Filed by: Eydelman MikhailNovember 5, 2024 4:08 PM Form 10-Q Vaxcyte, Inc. For: Sep 30November 5, 2024 4:06 PM Form 8-K Vaxcyte, Inc. For: Nov 05November 5, 2024 4:03 PM Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 4:01 PM Form 4 Vaxcyte, Inc. For: Nov 01 Filed by: PICKERING GRANTNovember 4, 2024 6:47 PM Form 4 Vaxcyte, Inc. For: Nov 01 Filed by: Wassil JimNovember 4, 2024 6:46 PM